Working memory networks and activation patterns in schizophrenia and bipolar disorder: comparison with healthy controls

Christine Lycke Brandt, Tom Eichele, Ingrid Melle, Kjetil Sundet, Andrés Server, Ingrid Agartz, Kenneth Hugdahl, Jimmy Jensen and Ole A. Andreassen

Background
Schizophrenia and bipolar disorder are severe mental disorders with overlapping genetic and clinical characteristics, including cognitive impairments. An important question is whether these disorders also have overlapping neuronal deficits.

Aims
To determine whether large-scale brain networks associated with working memory, as measured with functional magnetic resonance imaging (fMRI), are the same in both schizophrenia and bipolar disorder, and how they differ from those in healthy individuals.

Method
Patients with schizophrenia (n = 100) and bipolar disorder (n = 100) and a healthy control group (n = 100) performed a 2-back working memory task while fMRI data were acquired. The imaging data were analysed using independent component analysis to extract large-scale networks of task-related activations.

Results
Similar working memory networks were activated in all groups. However, in three out of nine networks related to the experimental task there was a graded response difference in fMRI signal amplitudes, where patients with schizophrenia showed greater activation than those with bipolar disorder, who in turn showed more activation than healthy controls. Secondary analysis of the patient groups showed that these activation patterns were associated with history of psychosis and current elevated mood in bipolar disorder.

Conclusions
The same brain networks were related to working memory in schizophrenia, bipolar disorder and controls. However, some key networks showed a graded hyperactivation in the two patient groups, in line with a continuum of neuronal abnormalities across psychotic disorders.

Declaration of interest
K.H. has stock ownership in NordicNeuroLab, which supplied audiovisual and other hardware equipment for the fMRI image acquisitions as well as software for fMRI data analysis. I.A. has served as an unpaid consultant for Eli Lilly. I.M. has received speaker’s honoraria from Janssen and AstraZeneca. O.A.A. has received speaker’s honoraria from AstraZeneca, Janssen, Bristol-Myers Squibb and GlaxoSmithKline.

Schizophrenia and bipolar disorder have similar clinical symptoms, and overlapping genetic factors have been implicated. Further, impairment of cognitive functions such as working memory is seen in both disorders. However, a limited number of studies have examined whether these disorders also have overlapping neural substrates related to cognitive task performance as measured for example with functional magnetic resonance imaging (fMRI). Impairment of working memory is considered a core feature of schizophrenia. Although deficits are present also in bipolar disorder, this has received less attention than in schizophrenia. In both disorders the impairment is stable over time and across different clinical states, is relatively resistant to treatment and contributes to poor functional outcome. In addition, neuroimaging studies have shown altered working memory activation in both disorders, but only two previous studies of working memory have compared schizophrenia and bipolar disorder in the same experiment, which makes working memory an important study target. Since it is a trait in both disorders, neural activation measured with fMRI during a working memory task can determine overlapping neurobiological substrates. Working memory involves not only the dorsolateral prefrontal cortex but also distributed brain networks, and may therefore reflect more widely distributed abnormalities that could be present in both disorders.

Although the working memory activation pattern has been well characterised in schizophrenia, it is less clear in bipolar disorder. Further, it remains unclear whether the working memory activation patterns differ between the disorders with regard to brain regions or activation levels (indicating differences in mechanisms). To draw conclusions about overlapping neurobiological substrates of working memory in schizophrenia and bipolar disorder, the groups should be compared in the same experiment, also including a healthy control group. Owing to the heterogeneity of patient samples, large well-characterised samples are needed. We used fMRI and independent component analysis (ICA) to investigate brain networks involved in working memory in people with schizophrenia ( n = 100), people with bipolar disorder ( n = 100) and healthy volunteers ( n = 100). Since the disorders share genetic susceptibility and have similar neurocognitive manifestations, we predicted that the two patient groups would have impairments in the same brain networks, and that there would be differences in both working memory performance and activation levels of the underlying networks in patients compared with controls. In addition, we explored how clinical, cognitive and behavioural factors were associated with the activation patterns across diagnostic groups.

Method
In total, 300 participants were included in the study, of whom 100 had a DSM-IV diagnosis of schizophrenia spectrum disorder (schizophrenia n = 75, schizoaffective disorder n = 14,
Lycke Brandt et al

schizophreniform disorder \( n = 11 \) and 100 had a diagnosis of bipolar disorder (type 1 \( n = 57 \), type 2 \( n = 43 \)). These groups are subsequently referred to as ‘schizophrenia’ and ‘bipolar disorder’ respectively. In addition, 100 healthy control participants were included. Patients were recruited consecutively from psychiatric units at four major hospitals in Oslo. The control group was randomly selected from the same catchment area as the patient group using statistical records (www.ssb.no). Of the control group, 28% replied to the invitation and consented to participate, and of these 37% underwent scanning. The current study is part of the Thematically Organised Psychosis (TOP) study,6 and is approved by the Regional Committee for Medical Research Ethics and the Norwegian Data Inspectorate. After complete description of the study to the participants, written informed consent was obtained according to the Declaration of Helsinki. To participate in the study all individuals had to be aged 18–65 years, speak a Scandinavian language and have the ability to undergo fMRI examination. Exclusion criteria were presence of a developmental disorder or serious brain damage, or having a metal implant or cardiac pacemaker. To ensure a healthy control group, these participants were screened with a questionnaire about severe mental illness and the Primary Care Evaluation of Mental Disorders,20 and were excluded if they or any of their first-degree relatives had a lifetime history of a severe psychiatric disorder (schizophrenia, bipolar disorder or major depression).

Clinical assessment

Patients were clinically characterised through a personal interview conducted by trained clinicians working as research fellows (MDs or psychologists). The interview covered diagnostics, symptoms, neurocognition, drug use and medication status.6 The psychiatric diagnosis was established using the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I).21 Diagnostic reliability was satisfactory,22 with overall agreement for DSM-IV diagnosis categories of 82% and overall \( \kappa = 0.77 \) (95% CI 0.60–0.94). Information from the SCID assessment showed that 56% of the patients were in remission from either affective or psychotic episode (bipolar disorder 74%, schizophrenia 37%). Of those not in remission (44%), 30% of the total number of patients were experiencing a psychotic episode (bipolar disorder 1%, schizophrenia 60%) and 14% an affective episode (bipolar disorder: 3% mania, 1% hypomania, 21% depression; schizophrenia: 3% depression). Complete data were missing for 17% of the patients. Symptom assessment on the day of scanning showed that psychotic or affective symptoms were present in less than a third of the patients in either diagnostic group, indicating that most patients had low symptom levels during the experimental task. The scanning was done on a different day from the diagnostic scanning of anatomy was done with a magnetisation prepared rapid acquisition gradient echo (MPRAGE) \( T_1 \)-weighted sequence with 80 sagittal slices: repetition time (TR) 2000 ms, echo time (TE) 3.95 ms, field of view (FOV) 256 × 256 mm\(^2\), flip angle (FA) 7\(^{\circ}\), matrix 128 × 128. Next, \( T_2^* \)-weighted functional imaging with 164 blood oxygen level-dependent (BOLD) whole brain measurements per condition was done with an echoplanar imaging (EPI) pulse sequence. Each EPI volume measurement consisted of 24 axial slices (TR = 2040 ms, TE = 50 ms, FOV 224 × 224 mm\(^2\), FA = 90\(^{\circ}\), matrix 64 × 64), with a pixel size of 3 mm in the axial plane and a slice thickness of 4 mm with 1 mm gap between slices. The first seven volumes and the last volume were discarded to avoid initial steady-state effects, leaving 156 images for analysis.

Preprocessing

Preprocessing of the fMRI data was done using the SPM5 software package (Wellcome Department of Imaging Neuroscience, www.fil.ion.ucl.ac.uk/spm/software/spm5/) implemented in Matlab 7.1 (MathWorks, Natick, Massachusetts, USA) running on a Windows platform. The preprocessing included realignment, spatial normalisation and smoothing, using a 6 mm full-width half-maximum smoothing kernel.

Independent component analysis

Group ICA was performed with the Group ICA of fMRI Toolbox (GIFT) (http://icatb.sourceforge.net/). First, the preprocessed fMRI data from each participant were intensity normalised through voxel-wise division of the time series mean (equivalent to percentage signal change) and global intensity offsets were removed between individual data-sets. Then, principal component analysis (PCA) was used to reduce the data from each participant. For the analyses presented here the number of retained principal components was set to 36, since this model order was the maximum across dimensionality estimations for each participant and yielded robust Icasso results.26 Using the Infomax ICA algorithm,27 group sources in the aggregate data were computed. To reduce sensitivity to initial conditions of Infomax and thereby estimate robust components, the ICA decomposition was repeated 100 times using the Icasso algorithm,26 and back-reconstruction presentations were implemented in E-Prime software (version 1.0; Psychology Software Tools, Sharpsburg, Pennsylvania, USA) and were presented through video goggles using the VisualSystem (NordicNeuroLab, Bergen, Norway). Behavioural responses were collected using the ResponseGrips system (NordicNeuroLab, Bergen, Norway) and the participants responded with their right or left index finger or thumb. Before scanning all participants underwent a short training procedure to ensure that they understood the task instructions. Immediately before the start of the experiment, task instructions were also shown in the goggles. The task was presented using a block design with four ON blocks (stimuli) and four OFF blocks (no stimulus). In each ON block there were 18 stimulus presentations, with 3 or 4 presentations being pseudo-randomised target stimuli (in total 13 targets). The stimulus duration was 300 ms and the interstimulus interval was 2500 ms. An ON block lasted for 52 s and was followed by an OFF block of 26 s during which only a fixation cross was presented and no task was performed.

Image acquisition

The data were acquired on a 1.5 T Siemens Magnetom Sonata (Siemens Medical Solutions, Erlangen, Germany) supplied with a standard head coil at Oslo University Hospital, Ullevål. Initial scanning of anatomy was done with a magnetisation prepared rapid acquisition gradient echo (MPRAGE) \( T_1 \)-weighted sequence with 80 sagittal slices: repetition time (TR) 2000 ms, echo time (TE) 3.95 ms, field of view (FOV) 256 × 256 mm\(^2\), flip angle (FA) 7\(^{\circ}\), matrix 128 × 128. Next, \( T_2^* \)-weighted functional imaging with 164 blood oxygen level-dependent (BOLD) whole brain measurements per condition was done with an echoplanar imaging (EPI) pulse sequence. Each EPI volume measurement consisted of 24 axial slices (TR = 2040 ms, TE = 50 ms, FOV 224 × 224 mm\(^2\), FA = 90\(^{\circ}\), matrix 64 × 64), with a pixel size of 3 mm in the axial plane and a slice thickness of 4 mm with 1 mm gap between slices. The first seven volumes and the last volume were discarded to avoid initial steady-state effects, leaving 156 images for analysis.

Experimental task

The working memory task was an n-back task involving consecutive presentations of pairs of numbers between 1 and 9.24,25 Since the aim of the study was to investigate brain networks, we applied only a 2-back condition, in which the participant was asked to press a response button when the two numbers were the same as the numbers shown two trials back in the sequence. The stimuli were subsequently referred to as ‘schizophrenia’ and ‘bipolar disorder’ respectively. In addition, 100 healthy control participants were included. Patients were recruited consecutively from psychiatric units at four major hospitals in Oslo. The control group was randomly selected from the same catchment area as the patient group using statistical records (www.ssb.no). Of the control group, 28% replied to the invitation and consented to participate, and of these 37% underwent scanning. The current study is part of the Thematically Organised Psychosis (TOP) study,6 and is approved by the Regional Committee for Medical Research Ethics and the Norwegian Data Inspectorate. After complete description of the study to the participants, written informed consent was obtained according to the Declaration of Helsinki. To participate in the study all individuals had to be aged 18–65 years, speak a Scandinavian language and have the ability to undergo fMRI examination. Exclusion criteria were presence of a developmental disorder or serious brain damage, or having a metal implant or cardiac pacemaker. To ensure a healthy control group, these participants were screened with a questionnaire about severe mental illness and the Primary Care Evaluation of Mental Disorders,20 and were excluded if they or any of their first-degree relatives had a lifetime history of a severe psychiatric disorder (schizophrenia, bipolar disorder or major depression).

Clinical assessment

Patients were clinically characterised through a personal interview conducted by trained clinicians working as research fellows (MDs or psychologists). The interview covered diagnostics, symptoms, neurocognition, drug use and medication status.6 The psychiatric diagnosis was established using the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I).21 Diagnostic reliability was satisfactory,22 with overall agreement for DSM-IV diagnosis categories of 82% and overall \( \kappa = 0.77 \) (95% CI 0.60–0.94). Information from the SCID assessment showed that 56% of the patients were in remission from either affective or psychotic episode (bipolar disorder 74%, schizophrenia 37%). Of those not in remission (44%), 30% of the total number of patients were experiencing a psychotic episode (bipolar disorder 1%, schizophrenia 60%) and 14% an affective episode (bipolar disorder: 3% mania, 1% hypomania, 21% depression; schizophrenia: 3% depression). Complete data were missing for 17% of the patients. Symptom assessment on the day of scanning showed that psychotic or affective symptoms were present in less than a third of the patients in either diagnostic group, indicating that most patients had low symptom levels during the experimental task. The scanning was done on a different day from the diagnostic interview, so current symptom levels were assessed also on the day of scanning, using an interview covering symptoms of psychosis, depression and elevated mood in the previous week.23 The symptoms were rated as present, possibly present or absent. In addition, regular psychopharmacological medication was recorded, as well as the use of alcohol and non-alcohol drugs (see Table 1).

Experimental task

The working memory task was an n-back task involving consecutive presentations of pairs of numbers between 1 and 9.24,25 Since the aim of the study was to investigate brain networks, we applied only a 2-back condition, in which the participant was asked to press a response button when the two numbers were the same as the numbers shown two trials back in the sequence. The stimulus...
Brain activation in schizophrenia and bipolar disorder

Statistical analysis

The amplitude data from the component time courses were submitted to an analysis of covariance (ANCOVA) model with gender and age as covariates to test for main effects of group, and post hoc t-tests were used to investigate differences between groups (control vs. bipolar disorder, bipolar disorder vs. schizophrenia and schizophrenia vs. control). The same analysis was conducted for the spatial maps in order to detect topographical features that supported a group difference after correction for covariates. Gender and age were included as covariates in all analyses, since these variables were significantly different between groups, but not directly linked to the illness.

Secondary analyses

For the independent components that showed group differences in the ANCOVA, follow-up analyses were conducted to investigate the effects of factors that might explain the main results, after correcting for gender and age. Individuals with missing data on any of the variables were excluded from the analysis including that variable.

Cognitive, demographic and substance use factors. For the total sample of 300 individuals, linear regression with group as a fixed factor was performed to test the effect of handedness, education, IQ score, alcohol use, non-alcohol drug use and smoking separately on the amplitude values, and to investigate to what degree each variable influenced the group effect from the main analysis.

Clinical variables. Linear regression was performed in the two patient groups separately to test the effect of lifetime episodes (history of psychosis, depression or mania), current symptoms (psychotic, depressive or elevated mood), illness duration and medication (antipsychotics, anti-epileptics/lithium, antidepressants, anxiolytics) separately on the amplitude values. Regarding lifetime psychotic or mood episodes, we focused on psychosis in the bipolar disorder group and depression and mania in the schizophrenia group, because the presence of psychotic episodes varies most in bipolar disorder (included in the diagnostic criteria of schizophrenia) and the variation in mood episodes is largest in schizophrenia (included in the diagnostic criteria of bipolar disorder). For the bipolar disorder group the effect of subgroup (type 1 or 2) was also tested. Similarly, the effect of schizophrenia spectrum subgroup (schizoaffective disorder, schizopreniform disorder or schizophrenia) was tested in the schizophrenia group.

Behavioural variables. For the total sample, linear regression with group as a fixed factor was performed to test the effects of accuracy and response time separately on the amplitude values, and to investigate to what degree each variable influenced the group effect from the main analysis. Further, the effects of accuracy and response time on the amplitude values were tested in each group separately.

Results

The demographic and clinical characteristics of the study participants are shown in Table 1 (a fully annotated version is given in online Table DS1).

Behavioural data

Performance on the working memory task, corrected for gender and age, was significantly different between the groups, with respect to both response accuracy ($F = 18.3, P < 0.001$) and response time ($F = 9.6, P < 0.001$) (Table 2). Both task performance measures showed a graded pattern, with results for participants with bipolar disorder lying between those of the control group and the schizophrenia group, with the control group showing the highest accuracy and the shortest response time (Fig. 1). For response accuracy there were significant differences for all group comparisons: schizophrenia vs. bipolar disorder ($P < 0.01$), bipolar disorder vs. control ($P < 0.01$) and schizophrenia vs. controls ($P < 0.01$). For response time there were significant differences between the patient groups ($P < 0.05$) and for schizophrenia vs. controls ($P < 0.001$). Patients with bipolar disorder were not significantly slower than controls ($P = 0.22$).

Similarly to the procedure for the fMRI data, we tested whether behavioural differences between groups could be explained by any of the demographic or clinical variables. First, ANCOVAs for the whole sample were performed to test the effect of handedness, education, IQ score, alcohol use and non-alcohol drug use separately on the behavioural data, corrected for gender and age. Then, ANCOVAs for each patient group were performed for the clinical variables (lifetime episodes, current symptoms level, illness duration and medication). The results for the whole sample showed that response accuracy was moderately dependent on education ($t = 4.0, P < 0.001$) and IQ score ($t = 7.2, P < 0.001$), and that response time marginally decreased with alcohol use ($t = 2.3, P < 0.05$). In the bipolar disorder group, response time was slightly shorter for patients with a history of depression ($t = 2.1, P < 0.05$) and current symptoms of depression ($t = 2.1, P < 0.05$), and longer for patients with a history of mania ($t = 3.2, P < 0.05$). Response time also increased with illness duration ($t = 2.1, P < 0.05$) in the bipolar disorder group. Individuals with missing data on any of the variables were excluded from the particular analyses.

Imaging data

Brain regions involved in the nine independent components that showed the largest signal changes in the working memory task across all participant groups are shown in Table 3 and Fig. 2 (left panel). Components 1–6 represent activations and components 7–9 represent deactivations that were correlated with the task. Figure 2 (right panel) also shows bar plots for the amplitude differences between groups for all components when variance accounted for by gender and age is removed from the data. Components 1, 3 and 4 showed significant ANCOVA differences, with a graded response pattern whereby patients in the schizophrenia group showed greater activation than those in the bipolar disorder group, who in turn showed more activation than the control group. The post hoc t-tests yielded significant differences between control and schizophrenia group participants in all three components, and between bipolar disorder and schizophrenia groups in component 1 (Table 4). Component 1 consisted of
frontal and parietal brain regions (overlapping with a frontoparietal network found to be involved in, for example, working memory), component 3 involved superior/inferior parietal regions (overlapping with a part of the dorsal attentional network) and component 4 included (for example) the insula and inferior frontal gyri (overlapping with a part of the executive control/salience network). For the remaining six components there was no significant group difference in the ANCOVA. However, in component 8 there was a significantly stronger activation in schizophrenia compared with bipolar disorder in an area of the right superior temporal gyrus (Montreal Neurological Institute peak coordinates 39, 12, 7). For the remaining six components there was no significant group difference in the ANCOVA. However, in component 8 there was a significantly stronger activation in schizophrenia compared with bipolar disorder in an area of the right superior temporal gyrus (Montreal Neurological Institute peak coordinates 39, 12, 7). For the remaining six components there was no significant group difference in the ANCOVA. However, in component 8 there was a significantly stronger activation in schizophrenia compared with bipolar disorder in an area of the right superior temporal gyrus (Montreal Neurological Institute peak coordinates 39, 12, 7).

Secondary analyses

Exploratory post hoc analyses aimed to investigate the main results more deeply, to find out if and how different variables could
explain the graded effect of diagnosis. Therefore, only nominal P-values are presented.

Cognitive, demographic and substance use factors
Neither hand preference, education, IQ score, alcohol use, non-alcohol drug use nor smoking separately had a significant effect on the amplitude value in any of the components when group was also included in the regression model. The group effect and the graded response pattern (controls < bipolar disorder < schizophrenia) from the main analysis remained for all variables in all three components, except for component 3 where the group effect disappeared (P = 0.65) when education was included in the model.

Clinical variables
Lifetime episodes. The focus here was on history of psychosis in the bipolar disorder group, and history of depressive and manic episodes in the schizophrenia group. In bipolar disorder there was a significant effect of history of psychosis in component 3, whereby patients with psychosis showed a higher amplitude value than patients without such lifetime episodes (t = 2.2, P = 0.028). In schizophrenia no difference was associated with a history of depression or mania. Additionally, in the bipolar disorder group, history of depression was associated with amplitude value in components 1 (t = 3.2, P = 0.002) and 3 (t = 2.0, P = 0.046), indicating differences in the mania-only subgroup (n = 9).

Current symptoms. In the bipolar disorder group, participants with elevated mood showed a lower amplitude value than those without elevated mood in components 3 (t = –3.0, P = 0.008) and 4 (t = –2.1, P = 0.038), whereas there was no effect of depressive or psychotic symptoms. In the schizophrenia group, no association with current symptom levels was found.
Illness duration. There was no effect of illness duration on any of the components.

Medication. In bipolar disorder there was a significant effect of anxiolytics in component 4 ($t = 2.1$, $P = 0.043$) but no effect of other medications. In schizophrenia there was an effect of anti-epileptics/lithium in component 1 ($t = 2.3$, $P = 0.022$), but no effect of other medications.

Subgroups. There was no effect of bipolar disorder or schizophrenia spectrum subgroups on any of the components.

Behavioural variables

Neither accuracy nor response time alone had a significant effect on the amplitude value in any of the components when group was also included in the regression model. The group effect from the main analysis remained significant for both variables in all components, except for accuracy in component 3. However, here the $P$-value for the group effect was just above the significance threshold ($P = 0.055$). The graded response pattern also remained in all components, except in component 1 when including response time, but this was probably affected by the exclusion of individuals with missing data (Table 2). The analysis of the effect of behavioural data on the amplitude values in each group separately showed that for accuracy there was no significant effect on the amplitude in any of the components in any of the groups. However, in the schizophrenia group there was a significant effect of response time on the amplitudes in all three components, where the amplitude values marginally decreased with response time (component 1 $t = -2.6$, $P = 0.013$; component 3 $t = -3.6$, $P = 0.001$; component 4 $t = -2.1$, $P = 0.043$). However, it is worth noting that 15 people with schizophrenia were excluded from this analysis because of missing response time data (Table 2.).

**Discussion**

Our main finding was activation in the same brain networks for schizophrenia, bipolar disorder and control groups during a working memory task, but with a graded increased activation in key networks from controls to schizophrenia, with bipolar disorder in between. Nine independent components of brain activation related to the working memory task were identified, of which six were activations in brain regions previously found to be involved in working memory in healthy individuals. These included areas in the dorsolateral (Brodmann areas (BAs) 9/46) and ventrolateral (BAs 44/45/47) prefrontal cortex, premotor cortex (BAs 6/32) and parietal cortex (BAs 7/40) in both hemispheres. The last three components were deactivations in regions consistent with the main sites of the default mode network.

**Similar networks but different activation patterns**

Mainly the same brain areas were engaged in both patient and control groups, i.e. no disease-specific network or compensatory region was detected. This supports the notion that there are only subtle network abnormalities underlying cognitive impairment in psychotic disorders. However, in three of the task-positive components (1, 3 and 4) there was a similar graded pattern of group differences in the amplitude of the fMRI signal, with participants in the bipolar disorder group showing stronger activation than the control group, and schizophrenia group participants showing stronger activation than both the control group and the bipolar disorder group. Considering the patients’ young age, short duration of illness and low prevalence of symptoms at the time of the fMRI scanning, these results support the presence of qualitatively similar neurobiological abnormalities across disorders, with differences in severity between diagnoses. In addition, we used a large sample size, which further indicates that the fMRI results obtained are robust, and which enables additional analysis of subgroups. This is in contrast to the few other studies in the field; so far, there have been only two reported neuroimaging studies of working memory with a direct comparison between schizophrenia and bipolar disorder. The first study was based on 20 and 21 patients with schizophrenia and bipolar disorder respectively, compared with 38 controls. The working memory task was also different, with sets of abstract designs, and not an $n$-back task, most commonly used in fMRI studies of working memory. The other study was a pilot study using a 2-back task, performed by 10 patients with schizophrenia, 12 patients with bipolar disorder and 22 healthy participants. Both studies focused mainly on the prefrontal cortex, where decreased activation (hypoactivation) was found in the dorsolateral part in schizophrenia compared with controls, whereas increased activation (hyperactivation) was reported in the medial part in schizophrenia compared with both bipolar disorder and controls.

**Hyperactivation**

Our results show that those in the patient groups had stronger activations than the control group. Several other neuroimaging studies of working memory have also shown hyperactivation in both bipolar disorder and schizophrenia, although not previously when compared with each other directly, except in the pilot study mentioned above. However, hypoactivation has also been a common finding. One explanation of these
inconsistent findings has been that the brain activation of people with schizophrenia and healthy controls may be represented by different, but overlapping, inverted U-curve shapes of activation. According to such a model, patients will show stronger activation than controls even if task difficulty is low. This fits well with the behavioural data from our study, which showed that both patient groups had a high performance level, and it suggests that the patients had to use more cognitive resources than the controls to perform the same task. The current results further suggest that the activation pattern in bipolar disorder fits into the same model, with a less abnormal inverted U-curve of activation compared with schizophrenia. However, the results may also partly reflect the graded pattern of task performance measures, with the bipolar disorder group results lying between the two other groups, even if the secondary analyses of task performance effects did not show any strong influence on the main results. Altogether, the grading of activation levels from controls to bipolar disorder to schizophrenia may reflect both the increased difficulty in task performance across groups and the compensatory increased recruitment of brain networks in patients.

**Working memory network**

The three components that showed group differences were all in frontal and parietal brain regions consistent with the well-known working memory network. Previous neuroimaging studies, most
of them in schizophrenia, have focused on and found abnormalities not only in the prefrontal cortex in particular (cf. the discussion about hyper- and hypoactivation) but also in the parietal cortex.12,33 It has been proposed that structural and functional alterations in schizophrenia might start in the parietal lobe and progress to frontal regions.35 One could speculate that the same applies to bipolar disorder, but with a lower magnitude. Further, the fact that we found group differences in components that involved all the typical working memory areas supports the notion that both schizophrenia and bipolar disorder involve abnormalities in a distributed network of brain regions, not only in single regions.12

Association with clinical variables

Secondary analyses were performed to investigate whether the finding of a graded response pattern across diagnoses could be explained by factors other than diagnostic group. The results showed that certain clinical variables were associated with time-course amplitudes. Most of the variation in amplitude values was found in bipolar disorder, where particularly component 3, involving parietal brain regions, seemed to be associated with clinical factors. However, the effect size was small for all variables. Of special interest, there was a significant effect of history of psychosis in component 3. Here, the bipolar disorder group patients with psychosis showed an amplitude response pattern that more closely resembled that of the schizophrenia group than that of the bipolar disorder group patients without such lifetime episodes. Thus, history of psychosis seemed to explain some of the graded response pattern in parietal regions. In bipolar disorder there was also an association between history of depression and amplitude value in two of the components, indicating differences in the mania-only subgroup (n = 9). Further, two components were associated with current elevated mood in bipolar disorder. Here, patients with elevated mood symptoms showed a response pattern that was more similar to that of the control group. In schizophrenia, neither lifetime episodes nor current symptoms seemed to affect the component time-course amplitudes. Regarding the impact of medication, there were few effects on amplitude value within each patient group. The only associations were found for anxiolytics in one component in bipolar disorder, and for anti-epileptics/lithium in one component in schizophrenia. This is in line with two reviews showing few general effects of medication on functional neuroimaging findings in schizophrenia and bipolar disorder.34,35 Except for the effects of these clinical characteristics, there were few variables that seemed to affect the main results. Altogether, the results of the secondary analyses indicate that the graded activation pattern across diagnostic groups is a robust phenomenon, which is in line with a continuum of neuronal abnormalities across psychotic disorders.

Implications

These findings add a new level of explanation to the overlapping clinical characteristics and genetic factors in schizophrenia and bipolar disorder.1,2,4 The results suggest that the two disorders should be perceived as dimensionally different, or different in the degree to which specific substrates or neural mechanisms are perturbed, rather than categorically separate entities. It could be speculated that the findings support the concept of a psychosis continuum.37–40 However, more research is needed before the neurobiological substrates can be implemented in future revisions of DSM.37–39

Funding

The study was financially supported by the Research Council of Norway (grant numbers 147754/V90, 163830/V50 and 183792/V50) and the South-Eastern (2004-123) and Western (91141) Norway Regional Health Authority.

Acknowledgements

The authors thank the study participants for their contribution, and the clinicians who were involved in patient recruitment and clinical assessments. Special thanks are due to Anne Hilde Fanstad and the staff at the Department of Radiology and Nuclear Medicine, Oslo University Hospital, and Eivind Bakken of the Thematically Organised Psychosis study, for providing technical assistance.

Christine Lycke Brandt, MSc, K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, and Division of Mental Health and Addiction, Oslo University Hospital, Oslo; Tom Eichele, MD, PhD, Department of Biological and Medical Psychology, University of Bergen, Bergen; Ingrid Melle, MD, PhD, K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, and Division of Mental Health and Addiction, Oslo University Hospital, Oslo; Kjetil Sundet, PhD, Department of Psychology, University of Oslo, K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, and Division of Mental Health and Addiction, Oslo University Hospital, Oslo; Andrés Server, MD, Section of Neuroradiology, Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo; Ingrid Agartz, MD, PhD, K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, and Division of Mental Health and Addiction, Oslo University Hospital, Oslo; Jimmy Jensen, PhD, Centre for Psychology, Kristianstad University, Kristianstad, Sweden; Kenneth Hugdahl, PhD, Department of Biological and Medical Psychology, University of Bergen, and Division of Psychiatry, Department of Radiology, Haukeland University Hospital, Bergen, Norway; Ole A. Andreassen, MD, PhD, K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, and Division of Mental Health and Addiction, Oslo University Hospital, Oslo; Ingrid Melle, MD, PhD, K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, and Division of Mental Health and Addiction, Oslo University Hospital, Oslo; Jimmy Jensen, PhD, Centre for Psychology, Kristianstad University, Kristianstad, Sweden; K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, and Division of Mental Health and Addiction, Oslo University Hospital, Oslo; Ole A. Andreassen, MD, PhD, K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, and Division of Mental Health and Addiction, Oslo University Hospital, Oslo; Ole A. Andreassen, MD, PhD, K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, and Division of Mental Health and Addiction, Oslo University Hospital, Oslo; Jimmy Jensen, PhD, Centre for Psychology, Kristianstad University, Kristianstad, Sweden; K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, and Division of Mental Health and Addiction, Oslo University Hospital, Oslo.

Correspondence: Christine Lycke Brandt, Division of Mental Health and Addiction, Psychosis Research Unit/TOP, Ullevål Hospital, Building 49, PO Box 4954 Nydalen, N-0434 Oslo, Norway. Email: c.l.brandt@medisin.uio.no

First received 18 Mar 2013, final revision 5 Jul 2013, accepted 25 Oct 2013
References


### Table D51 Demographic and clinical characteristics

<table>
<thead>
<tr>
<th>Schizophrenia group (n = 100)</th>
<th>Bipolar disorder group (n = 100)</th>
<th>Control group (n = 100)</th>
<th>Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Test</td>
</tr>
<tr>
<td>Demographics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender (male), n (%)</td>
<td>67 (67)</td>
<td>40 (40)</td>
<td>$\chi^2 = 14.9$</td>
</tr>
<tr>
<td>Age, years: mean (s.d.)</td>
<td>31.9 (7.7)</td>
<td>35.4 (11.4)</td>
<td>F = 3.9</td>
</tr>
<tr>
<td>Handedness (right), n (%)</td>
<td>87 (87)</td>
<td>89 (87)</td>
<td>$\chi^2 = 2.0$</td>
</tr>
<tr>
<td>Education, years: mean (s.d.)</td>
<td>13.0 (2.4)</td>
<td>13.3 (2.3)</td>
<td>F = 10.4</td>
</tr>
<tr>
<td>IQ score, mean (s.d.)</td>
<td>104.7 (14.8)</td>
<td>108.1 (12.5)</td>
<td>F = 16.2</td>
</tr>
<tr>
<td>Duration of illness, years: mean (s.d.)</td>
<td>6.4 (6.2)</td>
<td>6.7 (7.2)</td>
<td>F = 0.3</td>
</tr>
<tr>
<td>Comorbid disorders, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Substance use</td>
<td>23 (23)</td>
<td>23 (23)</td>
<td>$\chi^2 = 0.0$</td>
</tr>
<tr>
<td>Somatic illness</td>
<td>10 (11)</td>
<td>12 (13)</td>
<td>$\chi^2 = 0.29$</td>
</tr>
<tr>
<td>Lifetime episodes, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Psychosis</td>
<td>100 (100)</td>
<td>52 (52)</td>
<td>$\chi^2 = 63.2$</td>
</tr>
<tr>
<td>Psychosis in bipolar disorder types 1/2</td>
<td>45 (79)</td>
<td>7 (16)</td>
<td>$\chi^2 = 38.6$</td>
</tr>
<tr>
<td>Depression</td>
<td>56 (56)</td>
<td>91 (91)</td>
<td>$\chi^2 = 31.5$</td>
</tr>
<tr>
<td>Mania</td>
<td>8 (8)</td>
<td>57 (57)</td>
<td>$\chi^2 = 54.7$</td>
</tr>
<tr>
<td>Current symptoms, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Psychotic symptoms</td>
<td>29 (30)</td>
<td>17 (17)</td>
<td>$\chi^2 = 4.1$</td>
</tr>
<tr>
<td>Elevated mood symptoms</td>
<td>8 (8)</td>
<td>14 (14)</td>
<td>$\chi^2 = 1.8$</td>
</tr>
<tr>
<td>Depressive symptoms</td>
<td>24 (24)</td>
<td>31 (32)</td>
<td>$\chi^2 = 1.2$</td>
</tr>
<tr>
<td>Medication</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antipsychotics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n (%)</td>
<td>71 (76)</td>
<td>35 (38)</td>
<td>$\chi^2 = 27.0$</td>
</tr>
<tr>
<td>DDD, mean (s.d.)</td>
<td>1.10 (1.15)</td>
<td>0.29 (0.52)</td>
<td>F = 6.2</td>
</tr>
<tr>
<td>Anti-epileptics/lithium</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n (%)</td>
<td>8 (8)</td>
<td>58 (64)</td>
<td>$\chi^2 = 63.2$</td>
</tr>
<tr>
<td>DDD, mean (s.d.)</td>
<td>0.06 (0.30)</td>
<td>0.57 (0.63)</td>
<td>F = 7.1</td>
</tr>
<tr>
<td>Antidepressants</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n (%)</td>
<td>23 (25)</td>
<td>26 (29)</td>
<td>$\chi^2 = 0.4$</td>
</tr>
<tr>
<td>DDD, mean (s.d.)</td>
<td>0.35 (0.73)</td>
<td>0.42 (0.80)</td>
<td>F = 0.6</td>
</tr>
<tr>
<td>Anxiolytics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n (%)</td>
<td>7 (8)</td>
<td>7 (8)</td>
<td>$\chi^2 = 0.0$</td>
</tr>
<tr>
<td>DDD, mean (s.d.)</td>
<td>0.06 (0.21)</td>
<td>0.10 (0.37)</td>
<td>F = 0.9</td>
</tr>
<tr>
<td>Substance use</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcohol use (AUDIT score), mean (s.d.)</td>
<td>5.94 (6.13)</td>
<td>7.10 (6.02)</td>
<td>5.24 (3.25)</td>
</tr>
<tr>
<td>Non-alcohol drug use (DUDIT score), mean (s.d.)</td>
<td>2.53 (5.99)</td>
<td>2.26 (6.35)</td>
<td>0.29 (1.65)</td>
</tr>
<tr>
<td>Smoking, n (%)</td>
<td>37 (49)</td>
<td>39 (53)</td>
<td>$\chi^2 = 0.01$</td>
</tr>
</tbody>
</table>

AUDIT, Alcohol Use Disorders Identification Test; BD, bipolar disorder; DDD, defined daily dose; DUDIT, Drug Use Disorders Identification Test; HC, healthy controls; NA, not applicable; SZ, schizophrenia.

a. Tukey post hoc tests for all group comparisons, except for gender ($\chi^2$).
b. At the time of functional magnetic resonance imaging (fMRI).
c. The total number of years of completed education as reported by the participants (data from clinical examination, n = 294; data from neuropsychological testing, n = 6).
d. Wechsler Abbreviated Scale of Intelligence, n = 290; Wechsler Adult Intelligence Scale, n = 2. Missing in SZ group n = 4, missing in BD group n = 4.
e. Number of years between age at onset and age at fMRI scanning. Age at onset was defined as age at first contact with the mental health service due to a primary symptom (n = 194), age at first treatment with psychopharmacologicals (n = 4) or age at first experience of symptoms (n = 2).
f. Whether the patients had a lifetime diagnosis of alcohol or non-alcohol drug misuse or dependency. Alcohol/cannabis/other drugs diagnosis in SZ group 15/17/12%; in BD group 7/10/8%.
g. Whether the patients had a lifetime somatic illness; here included cardiovascular (SZ 2%, BD 2%), respiratory (SZ 7%, BD 8%), endocrine (SZ 1%, BD 4%), neurological (SZ 1%, BD 2%) or cancer (SZ 0%, BD 0%). Missing in SZ group n = 7, missing in BD group n = 10.
h. Whether or not the patient had a lifetime psychotic/depressive/manic episode. For most patients these variables were created based on information from the SCID interview (n = 194/188/199). When missing this information, other variables from the clinical interview were used to confirm the presence of a lifetime psychotic/depressive/manic episode: for history of psychosis, age at first contact with the mental health service due to positive psychotic symptoms (n = 4), for history of depression, age at first contact with the mental health service due to a depressive episode (n = 11) or age at first experience of SCID-verified symptoms of a depressive episode (n = 1), for history of mania, age at first experience of SCID-verified symptoms of a manic episode (n = 1).
i. Missing in SZ group n = 2, missing in BD group n = 2.
j. Defined daily dose (DDD): missing in SZ group: antipsychotics n = 7, anti-epileptics/lithium n = 10, antidepressants n = 9, anxiolytics n = 7, anti-epileptics/lithium n = 5, antidepressants n = 7, anxiolytics n = 7.
l. Whether the patients were daily smokers (yes/no) in the previous year. Missing in SZ group n = 25, missing in BD group n = 22.
Working memory networks and activation patterns in schizophrenia and bipolar disorder: comparison with healthy controls
Christine Lycke Brandt, Tom Eichele, Ingrid Melle, Kjetil Sundet, Andrés Server, Ingrid Agartz, Kenneth Hugdahl, Jimmy Jensen and Ole A. Andreassen
BJP published online January 16, 2014 Access the most recent version at DOI: 10.1192/bjp.bp.113.129254

Supplementary Material
Supplementary material can be found at:
http://bjp.rcpsych.org/content/suppl/2014/01/06/bjp.bp.113.129254.DC1

References
This article cites 0 articles, 0 of which you can access for free at:
http://bjp.rcpsych.org/content/early/2014/01/02/bjp.bp.113.129254#BIBL

Reprints/permissions
To obtain reprints or permission to reproduce material from this paper, please write to permissions@rcpsych.ac.uk

P<P
Published online 2014-01-16T00:05:27-08:00 in advance of the print journal.

You can respond to this article at
/letters/submit/bjprcpsych;bjp.bp.113.129254v1

Downloaded from
http://bjp.rcpsych.org/ on April 13, 2017
Published by The Royal College of Psychiatrists

Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include the digital object identifier (DOIs) and date of initial publication.

To subscribe to The British Journal of Psychiatry go to:
http://bjp.rcpsych.org/site/subscriptions/